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HELICOBACTER PYLORI INFECTION AND ITS IMPORTANCE IN THE DEVELOPMENT
OFIDIOPATHIC THROMBOCYTOPENIC PURPURA
Khashimova Zilola, MD, MBA, SP, Assistant Professor, MSPAS Program, Dominican University
of California, California, United States of America
Helicobacter Pylori (HP) infection has been associated with chronic inflammation of the stomach and may also
be associated with Idiopathic thrombocytopenic purpura (ITP).
A literature review was conducted on the reported research of HP infection associated with ITP.
Key words. Helicobacter Pylori, Idiopathic thrombocytopenic purpura, peptic ulcer, chronic gastritis, gastric
B cell lymphoma, hemostasis, autoimmune, hematological pathologies, gastric atrophy, platelets, gastric cancer.
HELICOBACTER PYLORI ИНФЕКЦИЯСИ ВА УНИ ИДИОПАТИК ТРОМБОЦИТОПЕНИК ПУРПУРА
РИВОЖЛАНИШИДАГИ АҲАМИЯТИ
Helicobacter pylori (HP) инфекцияси ошқозоннинг сурункали яллиғланиши ва ибиопатик тромбоцитопеник пурпура (ИТП) билан боғлиқ бўлиши мумкин. HP инфекциясини ўрганиш ва ИТП ривожланишига HP
инфекциясининг таъсир механизми бўйича илмий адабиётлар ўрганилди.
Калит сўзлар: Helicobacter Pylori, идиопатик тромбоцитопеник пурпура, ошқозон яраси, сурункали гастрит, ошқозоннинг B-хужайрали лимфомаси, гемостаз, аутоиммун касалликлар, гемотологик патологиялар, ошқозон атрофияси, тромбоцитлар, ошқозон саратони.
ИНФЕКЦИЯ HELICOBACTER PYLORI И ЕЕ ЗНАЧЕНИЕ ВРАЗВИТИИ ИДИОПАТИЧЕСКОЙТРОМБОЦИТОПЕНИЧЕСКОЙ ПУРПУРЫ
Инфекция Helicobacter Pylori (HP) связана с хроническим воспалением желудка и может также быть
связана с идиопатической тромбоцитопенической пурпурой (ИТП).Был проведен обзор научной литературы по исследованию инфекции HP и механизм влияния НР-инфекции на развитие ИТП.
Ключевые слова: Helicobacter Pylori, идиопатическая тромбоцитопеническая пурпура, язвенная болезнь желудка, хронический гастрит, B-клеточная лимфома желудка, гемостаз, аутоиммунные заболевания, гематологические патологии, атрофия желудка, тромбоциты, рак желудка.
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Introduction. Helicobacter pylori infection is a
recently re-examined gram-negative bacteria that
are radically changing the understanding of the
pathogenesis of peptic ulcer disease and, consequently, its treatment [1]. Since Helicobacter
pylori infection is related to many gastrointestinal
diseases including peptic ulcer, chronic active
gastritis, gastric B cell lymphoma and gastric cancer [2,3].
Helicobacter pylori (H. pylori) is a gram-negative, spiral-shaped, flagellated, microaerophilic
bacillus that colonizes the gastric mucosa and is
likely transmitted via the fecal–oral, or oral–oral
route during childhood [4–10]. Prevalent in more
than half of the world’s population, H. pylori infection occurs more frequently in developing nations [4,5,7]. There are documented differences
in virulence factors between Western and East
Asian strains of H. pylori, with the Eastern Asian
strains suspected to have higher pathogenicity in
relation to gastritis and gastric carcinoma [11,12].
Helicobacter pylori is recognized as a causative
agent for a variety of gastric diseases, including
gastritis, peptic ulcer, and gastric atrophy, and is
correlated with an increased risk for gastric cancer [13]. The bacterium has also been linked to
several extra-gastric diseases including nutritional deficiencies, such as vitamin B12 deficiency,
and hematological pathologies, such as idiopathic thrombocytopenic purpura (idiopathic immune-mediated thrombocytopenia, ITP) [14,15].

Helicobacter pylori infection (HP), causing
chronic inflammation of the stomach, is accompanied by the production of cytokines, signaling molecules, which causes activation of pro-inflammatory proteins and promotes intracellular mutations
not only locally, but also causes some systemic
effects and may affect other organs and systems
[1,2]. Numerous studies suggest a possible importance of the HP infection in the development
of several gastrointestinal diseases [3, 16]. The
list of these diseases is quite extensive, and in the
genesis of some of them the role of HP infection
can be regarded as proven, in others it is associated with only a part of the cases.It is sometimes
assumed the genesis role, but the available scientific data are contradictory, and therefore, require
further clarification. It is important to emphasize
here that extragastric symptoms usually develop
after years from the date of the HP-associated
gastritis, they can co-exist with it, but sometimes
are very long-term consequences of HP infection.
The severity of manifestations of extragastricdisorders initiated by HP does not correspond to the
severity of gastroduodenal pathology. In most
cases, extragastric manifestations of chronic gastritis activity is quite low, but to localize it usually
has a common character with the involvement of
the corpus.
It is well known that seropositivity for Helicobacter Pylori infection among healthy people in
the population varies considerably from country
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compared the features of the HP strains in patients with peptic ulcer and non-ulcer dyspepsia
and in patients with ITP, and found no significant
difference in the detection rate of the main factors
of HP pathogens such as CagA, VacA, iceA and
hpyIIIR/hrgA. However, they noted the same type
of chronic nature of HP-associated gastritis in all
patients with ITP, which is characterized by predominant involvement of the gastric body and inflammation activity was similar to that of patients
with gastric ulcer.
The mechanism of HP infection influence on
the development of ITP is not completely clear.
Some authors show the direct effect of HP on
platelet function, particularly M. Byrne et al. [23].
He showed that HP is able to bind von Willebrand
factor and interact with glycoprotein Ib, inducing
platelet aggregation. However, given that the other categories of patients (with peptic ulcer disease,
chronic gastritis), platelet count before and after
eradication does not change, therefore it is unlikely we are talking about the direct influence of HP
on platelets. Most likely, HP induces the formation
of antiplatelet autoantibodies by chronic immunologic stimuli arising from chronic inflammation or
with HP some antigenic similarity and platelets in
a certain category of patients. However, not only
NO, but a variety of viral infections may be cause
of ITP, including Epstein-Barr virus (EBV). However, in this case ITP usually has an acute rather
than a chronic condition [24]. Perhaps the coexistence of two chronic infections (HP + EBV) may
be more likely to be realized in the chronic ITP in
genetically predisposed subjects. T. Suzuki et al.
found that the genotype of TGF-b (G / G or G / A)
may predispose to an increase in platelet count
after eradication of HP [25,26].
Conclusion. Describing the reasons for ITP
as a whole, we can conclude that HP infection
is a factor of development in some patients with
ITP. Therefore, probably, ITP can be divided into
2 categories: HP-associated and independent. All
patients with ITP should be evaluated for HP (serologically or by using breath test), and upon detection of HP its eradication should be considered
as the first stage of treatment. If the effect of the
eradication is positive the further treatment of ITP
is not required. In cases the absence of effect it is
advisable to appoint pathogenic therapy of ITP.
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to country. This means that the number of people
who are carriers of Helicobacter Pylori infection
decreased over the past decades in the industrialized countries, and that it increases with age.
According to most studies, on the different series of patients, most of the authors have found a
high prevalence of Helicobacter Pylori infection in
patients with idiopathic thrombocytopenic purpura. According to the authors, most previous studies involving a fairly large number of patients have
been conducted in Italy and Japan. It has been
studied that in these countries the prevalence of
Helicobacter Pylori infection in healthy population
is high (> 70% over the age of 50 years) [5,6], so
the prevalence of Helicobacter Pylori infection in
patients with idiopathic thrombocytopenic purpura
in these countries cannot be given than among
the healthy population.
For the first time the assumption of the association between HP infection and ITP infection
was made by A. Gasbarrini et al., who reported
an increase in the number of platelets in a patient with ITP after HP eradication [19]. Since a report by Gasbarrini et al. in 1998, an accumulating
body of evidence has proposed a pathophysiological link between ITP and chronic Helicobacter
pylori (H. pylori) infection. Clinical reports have
described a spontaneous resolution of ITP symptoms in about 50% of chronic ITP patients following empirical treatment of H. pylori infection, but
response appears to be geography dependent.
Subsequently, this relationship was confirmed by
the detection of antibodies to HP and the positive results of respiratory urease test in 70-85%
of patients with ITP [8]. G. Emilia et al. [9] showed
a 50% efficiency of HP eradication treatment of
patients withITP. After successful eradication of
HP, most patients show a significant decrease
in the level of anti-platelet antibodies (AT-IgG).In
the paper T. Ando et al. [10], the platelet count
was normalized, after successful eradication was
achieved in 67% of patients, while without HP
eradication therapy none of the patients has improvement. It is important that the effect of eradication therapy has a long-term nature and is accompanied by a further increase of the number of
platelets to the rules after the end of treatment,
and it is saved for at least 2 years and does not
require any further treatment. T. Ando et al. [22]
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